Retinoic acid receptor responder (Tazarotene-induced gene) 1 (RARRES1, alias TIG1), initially identified as a downstream target of retinoic acid signaling [1], was demonstrated to be inactivated in primary tumors and cell lines of human cancers. The gene discussed is RARRES1; the disease is cancer.